LungLife AI Signs Exclusive U.S. Distribution Deal for Lung Cancer Diagnostic Test

LungLife AI, Inc. (LSE:LLAI) has announced an exclusive licensing and distribution agreement with Circulogene Theranostics, Inc. for the commercialization of its LungLB® test in the United States. The partnership includes an upfront payment and ongoing royalty fees, along with a potential option for Circulogene to acquire the licensed intellectual property. Finalization of the deal remains subject to shareholder approval and other necessary consents.

This agreement is expected to enhance LungLife’s financial stability and operational outlook while reinforcing its strategic focus on the U.S. diagnostics market. It also marks a significant milestone in expanding access to the LungLB® test, which supports early detection of lung cancer—a critical factor in improving patient outcomes.

About LungLife AI, Inc.

LungLife AI is a clinical diagnostics company specializing in the early detection of lung cancer. Its flagship product, the LungLB® test, is designed to aid in the timely diagnosis and monitoring of lung cancer, potentially transforming patient care. The company is actively pursuing U.S. market growth through targeted collaborations and distribution agreements.

• Year-to-Date Price Performance: -89.41%

• Average Daily Trading Volume: 359,269 shares

• Technical Sentiment: Bullish (Buy)

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  ActivTrades

• 

  Mark Austin

• 

  Capital Spreads

• 

  Neto Trade Analysis Department